Your shopping cart is currently empty

LQVTDSGLYRCVIYHPP (LP17) is a peptide and TREM-1 (Triggering Receptor Expressed on Myeloid cells 1) inhibitor derived from a highly conserved sequence between the extracellular structural domains of mouse and human TREM-1 and TLT-1.LP17 inhibits TREM-1 activation through a decoy receptor LP17 inhibits TREM-1 activation by actin through a decoy receptor mechanism, which has the advantage of penetrating the brain barrier and attenuating neuronal damage and inflammatory responses.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $60 | - | In Stock | |
| 5 mg | $147 | - | In Stock | |
| 10 mg | $263 | - | In Stock | |
| 25 mg | $446 | - | In Stock | |
| 50 mg | $645 | - | In Stock | |
| 100 mg | $886 | - | In Stock | |
| 500 mg | $1,790 | - | In Stock |
| Description | LQVTDSGLYRCVIYHPP (LP17) is a peptide and TREM-1 (Triggering Receptor Expressed on Myeloid cells 1) inhibitor derived from a highly conserved sequence between the extracellular structural domains of mouse and human TREM-1 and TLT-1.LP17 inhibits TREM-1 activation through a decoy receptor LP17 inhibits TREM-1 activation by actin through a decoy receptor mechanism, which has the advantage of penetrating the brain barrier and attenuating neuronal damage and inflammatory responses. |
| In vitro | In primary rat microglial cells, LQVTDSGLYRCVIYHPP (100 nM, 1-hour pretreatment) significantly inhibited hemoglobin-induced inflammation by reducing the expression of TREM-1, TNF-α, IL-1β, IL-6, and iNOS. It also decreased nitric oxide production and suppressed NF-κB p65 nuclear translocation, indicating strong anti-inflammatory effects[1]. |
| In vivo | In a rat model of subarachnoid hemorrhage (SAH), intracerebroventricular injection of LQVTDSGLYRCVIYHPP (0.5 μg) significantly suppressed TREM-1 and proinflammatory cytokine expression, reduced neuronal apoptosis, and improved neurological scores, demonstrating potent anti-inflammatory and neuroprotective effects[1]. |
| Synonyms | LP17 |
| Molecular Weight | 1961.24 |
| Formula | C89H137N23O25S |
| Cas No. | 887255-16-5 |
| Smiles | C(=O)([C@H]1N(C([C@H](CC2=CN=CN2)NC([C@H](CC3=CC=C(O)C=C3)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC4=CC=C(O)C=C4)NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC(C)C)N)=O)CCC(N)=O)=O)C(C)C)=O)[C@@H](C)O)=O)CC(O)=O)=O)CO)=O)=O)CC(C)C)=O)=O)CCCNC(=N)N)=O)CS)=O)[C@H](C)C)=O)[C@H](CC)C)=O)=O)=O)CCC1)N5[C@H](C(O)=O)CCC5 |
| Sequence | Leu-Gln-Val-Thr-Asp-Ser-Gly-Leu-Tyr-Arg-Cys-Val-Ile-Tyr-His-Pro-Pro |
| Sequence Short | LQVTDSGLYRCVIYHPP |
| Storage | keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | H2O: 10 mg/mL (5.1 mM), when pH is adjusted to 3 with CH3COOH. Sonication and heating are recommended. DMSO: 15 mg/mL (7.65 mM), when pH is adjusted to 7 with CH3COOH. Sonication and heating are recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
H2O/DMSO
| ||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.